CL2017003151A1 - Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas - Google Patents

Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas

Info

Publication number
CL2017003151A1
CL2017003151A1 CL2017003151A CL2017003151A CL2017003151A1 CL 2017003151 A1 CL2017003151 A1 CL 2017003151A1 CL 2017003151 A CL2017003151 A CL 2017003151A CL 2017003151 A CL2017003151 A CL 2017003151A CL 2017003151 A1 CL2017003151 A1 CL 2017003151A1
Authority
CL
Chile
Prior art keywords
prepare
methods
formulations
vaccines against
neoplasia
Prior art date
Application number
CL2017003151A
Other languages
English (en)
Inventor
Edward F Fritsch
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of CL2017003151A1 publication Critical patent/CL2017003151A1/es
Priority to CL2019003264A priority Critical patent/CL2019003264A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A UNA FORMULACIÓN PARA COMPOSICIÓN DE VACUNA O COMPOSICIÓN INMUNÓGENA CONTRA LA NEOPLASIA PARA EL TRATAMIENTO O PREVENCIÓN DE LA NEOPLASIA EN UN SUJETO Y A MÉTODOS PARA PREPARAR LA MISMA.</p>
CL2017003151A 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas CL2017003151A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172890P 2015-06-09 2015-06-09

Publications (1)

Publication Number Publication Date
CL2017003151A1 true CL2017003151A1 (es) 2018-04-06

Family

ID=56236097

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003151A CL2017003151A1 (es) 2015-06-09 2017-12-07 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003264A CL2019003264A1 (es) 2015-06-09 2019-11-14 Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)

Country Status (19)

Country Link
US (1) US20190060428A1 (es)
EP (1) EP3307303A2 (es)
JP (2) JP2018521028A (es)
KR (1) KR20180016531A (es)
CN (1) CN107921107A (es)
AU (1) AU2016276704A1 (es)
CA (1) CA2988135A1 (es)
CL (2) CL2017003151A1 (es)
CO (1) CO2017012893A2 (es)
CR (1) CR20180015A (es)
EC (1) ECSP18001613A (es)
HK (2) HK1252325A1 (es)
IL (1) IL256173A (es)
MX (1) MX2017015881A (es)
PE (1) PE20180601A1 (es)
PH (1) PH12017502233A1 (es)
RU (2) RU2753246C2 (es)
TW (2) TWI750122B (es)
WO (1) WO2016201049A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2788863T3 (es) 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CN108025048B (zh) 2015-05-20 2022-10-25 博德研究所 共有的新抗原
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
NZ759818A (en) 2017-10-16 2022-04-29 Illumina Inc Semi-supervised learning for training an ensemble of deep convolutional neural networks
US11861491B2 (en) 2017-10-16 2024-01-02 Illumina, Inc. Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs)
WO2019204663A1 (en) * 2018-04-19 2019-10-24 Neon Therapeutics, Inc. Peptide formulations and uses thereof
WO2020131586A2 (en) * 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
GB202104715D0 (en) 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN113461805B (zh) * 2021-09-02 2021-12-10 广州吉妮欧生物科技有限公司 一种嵌入抗原表位肽的荧光素酶及其构建方法和应用
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
CA2005291C (en) 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
US6780407B1 (en) 1989-03-08 2004-08-24 Aventis Pasteur Pox virus comprising DNA sequences encoding CEA and B7 antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US6277558B1 (en) 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
AU1588092A (en) 1991-02-22 1992-09-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Transmission blocking vaccine against malaria
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5766597A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Malaria recombinant poxviruses
US5756101A (en) 1991-07-01 1998-05-26 Pasteur Merieux Serums Et Vaccins Malaria recombinant poxvirus
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5849303A (en) 1995-06-07 1998-12-15 American Home Products Corporation Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
CN1195863C (zh) 1996-10-17 2005-04-06 牛津生物医学（英国）有限公司 逆转录病毒载体
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
AU9397098A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Methods and cell line useful for production of recombinant adeno-associated viruses
US6346415B1 (en) 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2002538770A (ja) 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6793926B1 (en) 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
ES2312344T3 (es) 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
EE05633B1 (et) 2000-03-14 2013-02-15 Mayr Anton Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
US20030104008A1 (en) 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
PL220781B1 (pl) 2002-04-19 2016-01-29 Bavarian Nordic As Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN
JP2006528647A (ja) 2003-07-24 2006-12-21 メリアル リミテッド 新規ワクチン製剤
RU2285548C2 (ru) * 2004-10-25 2006-10-20 Георгий Цыренович Дамбаев Способ лечения онкозаболеваний
LT2578685T (lt) 2005-08-23 2019-06-10 The Trustees Of The University Of Pennsylvania Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
EP2131857B1 (en) * 2007-03-22 2015-07-29 The Regents of the University of Colorado, a body corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2225002A4 (en) 2007-12-31 2011-06-22 Nanocor Therapeutics Inc RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES
ES2788863T3 (es) * 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
PT3892295T (pt) * 2011-05-24 2023-06-01 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacinas individualizadas para o cancro
KR102341899B1 (ko) * 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
EP3076992B1 (en) * 2013-12-06 2022-04-06 The Broad Institute, Inc. Formulations for neoplasia vaccines

Also Published As

Publication number Publication date
CO2017012893A2 (es) 2018-05-21
PE20180601A1 (es) 2018-04-09
WO2016201049A2 (en) 2016-12-15
TWI750122B (zh) 2021-12-21
RU2753246C2 (ru) 2021-08-12
JP2018521028A (ja) 2018-08-02
HK1253271A1 (zh) 2019-06-14
IL256173A (en) 2018-02-28
TW201718000A (zh) 2017-06-01
RU2017145963A (ru) 2019-07-16
KR20180016531A (ko) 2018-02-14
EP3307303A2 (en) 2018-04-18
CR20180015A (es) 2018-03-20
HK1252325A1 (zh) 2019-05-24
RU2021122284A (ru) 2021-10-21
CN107921107A (zh) 2018-04-17
MX2017015881A (es) 2018-04-18
TW202241500A (zh) 2022-11-01
ECSP18001613A (es) 2018-05-31
CL2019003264A1 (es) 2020-02-14
RU2017145963A3 (es) 2019-07-17
US20190060428A1 (en) 2019-02-28
CA2988135A1 (en) 2016-12-15
WO2016201049A3 (en) 2017-02-09
AU2016276704A1 (en) 2017-12-14
JP2021152053A (ja) 2021-09-30
PH12017502233A1 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
EP3463440A4 (en) NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
BR112016012862A2 (pt) formulações para vacinas para neoplasia
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
BR112017001796A2 (pt) composições de flagelina e seus usos
BR112017012804A2 (pt) composições para higiene bucal e métodos de uso.
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
MA45381A (fr) Formulation de vaccin contre le vih
PH12017500304A1 (en) Vaccine compositions against dengue virus diseases
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
CL2015000608A1 (es) Formulaciones de daptomicina y usos de la misma
CO2018012180A2 (es) Métodos de tratamiento para enfermedades colestásicas y fibróticas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
GB2556002B (en) Methods and compositions for nanoemulsion vaccine formulations
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
HK1258252A1 (zh) 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途
ZA201703467B (en) Methods of treating ocular conditions
SG11201911930SA (en) Methods and compositions for substance use disorder vaccine formulations and uses thereof
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
EP3270897A4 (en) Immunogenic compositions for use in vaccination against bordetella
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201890911A1 (ru) Комбинация тразодона и габапентина для лечения боли
BR112017004735A2 (pt) formulação antimicrobiana, e, formulação de concentrado antimicrobiano.
NZ725354A (en) Transdermal formulations of pergolide and uses thereof